 BERWYN, PA ACCESSWIRE April 5, 2021 Virpax Pharmaceuticals, Inc. Virpax or the Company NASDAQ:VRPX, a company specializing in developing pharmaceutical product candidates for pain management, today announced the results of a sciatic nerve preclinical study in rabbits designed to evaluate nerve damage from locally injected ProbudurTM, Virpaxs liposomal bupivacaine product candidate. Local anesthetics can be neurotoxic, particularly in doses and concentrations larger than those used clinically. 